|
DOCTORS
and parents have long been left to guess at which
children with a diagnosis of attention-deficit
hyperactivity disorder, or ADHD, will go on to become
adults with significant attention problems, how well
they will navigate the challenges of adulthood and
whether early recognition of—and medication for—their
condition will make a difference in the trajectory of
their lives.
Now a
series of studies following 457 Finnish children from
birth to ages 16 to 18 offers a glimpse of how the
primary symptoms of ADHD typically evolve. At the same
time, the studies raise provocative questions about the
long-term effect of treating those symptoms with
medication.
The
studies focus on a subset of 188 Finnish teens
considered to have “probable or definite ADHD” that will
follow them into adulthood and 103 kids with conduct
disorder—behavior issues that fall short of an ADHD
diagnosis but put kids at higher risk for similar
problems. Those teens were compared with a group of
Finnish teens with no ADHD diagnosis.
Researchers found it is the can’t-sit-still kids—the
stereotype of the “ADHD generation”—who are most likely
to mature out of the disease. Among those with
persistent ADHD, they also found, half have problems
with cognitive skills that are key to success in
adulthood, but half have no such deficits.
And when
researchers compare the findings from Finland with
studies of Americans with ADHD, an even more intriguing
discovery emerges: By the time they’re in their late
teens, those who receive drugs for attention problems
seem to fare about the same as those who do not.
That is
sure to fuel a simmering debate over the extent to which
American kids with ADHD receive medication, often with
little other support. In Finland medication for ADHD is
extremely rare.
“This
begs the question: Are current treatments really leading
to improved outcome over time?’” wrote neuropsychologist
Susan L. Smalley and coauthor Dr. Marjo-Riitta Jarvelin
in a special section of December’s Journal of the
American Academy of Child & Adolescent Psychiatry.
Smalley codirects the Center for Neurobehavioral
Genetics at the University of California, Los Angeles.
Jarvelin is a professor of public health and of medicine
at Imperial College School of Medicine in London and
University of Oulu, Finland, respectively.
UCLA
neuroscientist Robert Bilder, who was not involved in
the Finnish research, said the studies suggest that ADHD
might best be treated, in some kids, by shoring up
weaknesses in underlying cognitive skills rather than by
focusing exclusively on behavioral symptoms that can
change with age.
“We all
hope in the future we’ll find the optimal combination of
treatments—whether behavioral or pharmacological—that’ll
provide young people with these problems the best chance
to succeed in school and social environments,” Bilder
said. “It’s clear so far that no treatment’s been
identified that’s a panacea.”
Two
decades ago, as the diagnosis and medication of American
children with ADHD began to soar, researchers and
psychiatrists scarcely entertained the possibility of
adults with ADHD. Today experts estimate that 4.4
percent of American adults—more than 10 million
people—suffer from attention problems serious enough to
warrant a diagnosis of ADHD.
But like
the generation of children first diagnosed in large
numbers with ADHD, research on what the disorder looks
like across the life span has just begun to mature.
The new
research suggests that, as children with ADHD grow into
adolescence, it is the dreamy, forgetful, inattentive
types who are most likely to continue to struggle with
the disorder—especially if they also suffered from
depression, anxiety or serious behavior problems in
their preteen years. When their childhood symptoms
included hyperactivity and impulsiveness as well as
inattentiveness, their chances of having adult ADHD grew
higher still.
Underscoring the strong role of genes in the development
of attention deficit disorders, the studies found that a
child’s likelihood of having ADHD that persists into
adulthood is significantly greater if either parent—but
especially his or her father—suffers from serious
attention problems too.
By
contrast, those whose childhood symptoms were confined
to hyperactivity are the most likely to mature out of
the disease in adolescence, the Finnish studies found.
By age 18, most with persistent ADHD will struggle with
mental rather than physical restlessness.
In all,
roughly two in three of the Finnish children who were
diagnosed with ADHD as children continued to exhibit
severe attention problems between ages 16 and 18.
In an
introduction to the special section, Smalley points out
several similarities and one intriguing difference
between the Finnish children who were studied and their
US
counterparts. ADHD appears with similar frequency in
each of the two populations. Each population also has
similar variations in symptoms of the disorder and
similarly high rates of social and emotional
problems—depression, anxiety, defiant behavior—that
often afflict adolescents and adults with ADHD.
In
Finland, as in studies of US populations, about half of
older teens with persistent ADHD performed poorly on
tests of short-term, or working memory, and in cognitive
skills that are key to problem-solving, making plans and
executing tasks. And in each group, roughly the same
proportion of children “mature out” of the disorder.
Although
about 60 percent of American children diagnosed with
ADHD are medicated—at least at some point—for its
symptoms, virtually no Finnish children are given
medication. And yet, by the time they reach 16 to 18
years old, these two populations look very much the
same.
In an
interview, Smalley stressed that the studies do not cast
doubt on the short-term benefits a child with ADHD might
get from a stimulant or other medication that treats the
symptoms of the disorder. She cited recent studies
showing that at the end of one year, children medicated
for ADHD symptoms function better at home and school
than those who get behavioral and cognitive therapy. But
after three years, the difference between the two groups
begins to wane.
“We
really need to look at how effective, really, is
medication alone in long-term prevention” of the
intellectual deficits and psychiatric problems that
plague those with ADHD at higher rates than those
without, Smalley said.
She also
emphasized that the studies show that ADHD is “an
extreme on a continuum” of normal for humans. Just as
kids range across a spectrum in glucose tolerance or
reading ability—putting some at higher risk of diabetes
or dyslexia—they are also distributed across a spectrum
in terms of their ability to focus, the strength of
their working memory and their propensity for developing
social and emotional problems. As children age, some
will “age out” of the disorder, no longer meeting
diagnostic standards for ADHD.
If
better medication or specialized therapy, or both, can
drive down the risks that these children will be hobbled
by academic failure, ill-chosen impulses and other
psychiatric problems, their other talents could shine
through, Smalley said. And the world would be a better
place for it, she added.
“We need
to step back and embrace neurodiversity, diversity in
human behavior and try to work on ways to embrace and
enhance being at the extreme, instead of only focusing
on the deficits and disorder aspects of ADHD,” Smalley
said. |